Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), an incretin hormone that regulates blood sugar and appetite.
It works by activating GLP-1 receptors, which stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. Semaglutide is FDA-approved for type 2 diabetes (Ozempic®, Rybelsus®) and chronic weight management (Wegovy®). Beyond these approved uses, it is being studied in research for cardiovascular health, fatty liver disease, and neuroprotection. Use outside of FDA-approved indications remains experimental.
How It Is Used in Research Settings
- Studied for weight loss through appetite suppression and reduced caloric intake.
- Investigated for improving insulin sensitivity and glucose control in metabolic models.
- Explored in cardiovascular research for reducing inflammation and atherosclerosis risk.
- Examined in fatty liver disease (NAFLD/NASH) and neurodegenerative disease models.
Proposed Uses (Research Areas)
- Obesity and weight management research.
- Type 2 diabetes and insulin resistance studies.
- Cardiovascular and lipid metabolism research.
- Liver health — NAFLD and NASH models.
- Neuroprotection and cognitive function research.
How It Is Dosed in Research Settings
- Injectable (Subcutaneous): Studied at weekly doses ranging from 0.25 mg to 2.4 mg, with gradual titration to improve tolerance.
- Oral: Investigated in tablet form (Rybelsus®) at 7–14 mg daily for type 2 diabetes research.
- Cycle length: Clinical research often spans 16–68 weeks, reflecting long-term metabolic and weight management endpoints.
- Handling: Provided as pre-formulated injection pens or tablets in clinical research; stored refrigerated for stability.
Important Considerations
- Regulatory status: FDA-approved for type 2 diabetes and weight management. All other uses remain experimental.
- Evidence base: Large clinical trials demonstrate effectiveness for weight loss, glycemic control, and cardiovascular risk reduction. Research is ongoing in liver and neurological health.
- Safety: Reported side effects include nausea, vomiting, diarrhea, delayed gastric emptying, and rare risks such as pancreatitis or gallbladder disease. Long-term safety outside approved indications is under investigation.
Disclaimer
This material is provided for educational purposes only and summarizes published research on Semaglutide.
It is not medical advice. Except for its narrow FDA-approved indications, Semaglutide is considered experimental and should not be viewed as a therapy for medical use.
This peptide is for research use only.